VKTX
Viking Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website vikingtherapeutics.com
- Employees(FY) 23
- ISIN US92686J1060
Performance
+5.56%
1W
+4.13%
1M
+223.49%
3M
+664.75%
6M
+327.78%
YTD
+248.25%
1Y
Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Investment Analysis Report: VKTX
Overview
VKTX is a pharmaceutical company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $3.64 billion. In this report, we will conduct a comprehensive analysis of VKTX's financial statements to evaluate its valuation, fin...
Technical Analysis of VKTX 2024-05-03
Overview:
In analyzing the technical indicators for VKTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for VKTX stock.
T...
Recent News & Updates
- 2024-05-06 09:10
- 2024-05-06 03:10
- 2024-05-03 03:05
- 2024-04-30 23:59
- 2024-04-28 10:30
Is Viking Therapeutics Incredibly Undervalued?(Motley Fool)
- 2024-04-27 21:07
Can This High-Flying Stock 10x in 10 Years?(Yahoo Finance)
- 2024-04-26 06:00
3 Biotech Stocks to Buy on the Dip: April 2024(InvestorPlace)
- 2024-04-25 20:15
- 2024-04-25 18:00
3 Biotech Stocks to Buy on the Dip: April 2024(Investorplace)
- 2024-04-25 10:30
3 Millionaire-Maker Biotech Stocks(Motley Fool)
- 2024-04-25 09:01
- 2024-04-25 07:37
Q1 2024 Viking Therapeutics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-04-25 03:20
- 2024-04-24 23:28
11 Oversold MidCap Stocks To Buy Now(Insidermonkey)
- 2024-04-24 17:37
- 2024-04-24 17:32
- 2024-04-24 16:05
- 2024-04-24 11:36
3 Biotech Stocks With Skyrocketing Potential: April 2024(InvestorPlace)
- 2024-04-24 08:57
- 2024-04-24 08:00
3 Red-Hot Biotech Rockets Blasting Off in 2024(InvestorPlace)
- 2024-04-24 05:50
- 2024-04-24 04:05
- 2024-04-23 16:43
- 2024-04-23 09:15
Better Buy: Pfizer vs. Viking Therapeutics(Motley Fool)
- 2024-04-21 18:00
- 2024-04-19 17:45
- 2024-04-19 11:16
- 2024-04-19 05:45
- 2024-04-18 23:16
- 2024-04-17 16:05
Page 1 of 10
previousnext